Page last updated: 2024-11-10
prohexadione-ca
Description
prohexadione-Ca: a 2-oxoglutarate-dependent dioxygenase inhibitor reduces the incidence and severity of fire blight caused by Erwinia amylovora and other plant diseases [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
prohexadione(2-) : An organic anion derived from prohexadione by deprotonation of both the carboxy group and a hydroxy group of any of the enolate forms of the triketo moiety. The corresponding calcium salt, prohexadione-calcium, is used as an anti-lodging agent in small-grain cereals. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (6)
Synonym |
calcium 4-(1-oxidopropylidene)-3,5-dioxocyclohexanecarboxylate |
CHEBI:137424 |
prohexadione(2-) |
3-oxido-5-oxo-4-propionylcyclohex-3-ene-1-carboxylate |
4-(1-oxidopropylidene)-3,5-dioxocyclohexane-1-carboxylate |
prohexadione-ca |
Research
Studies (12)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (41.67) | 29.6817 |
2010's | 7 (58.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 22.62
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 22.62 (24.57) | Research Supply Index | 2.56 (2.92) | Research Growth Index | 4.60 (4.65) | Search Engine Demand Index | 21.17 (26.88) | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 12 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |